ty -jour t1-法国，德国，意大利和英国JF的哮喘的口服皮质类固醇处方模式 - 欧洲呼吸杂志- 国王，伊丽莎白·盟（Elizabeth au） - 萨尔卡尔（Sarkar），拉吉夫·阿（Rajiv Au） - 纳恩（Nan），卡桑德拉（Cassandra au） - 鲁比诺（Rubino），鲁比诺（Rubino），annalisa au -O'Leary，Caroline au -Muzwidzwa，Ruvimbo au，Belton，Laura，Laura Au-ur -http：//www.qdcxjkg.com/content/early/2020/03/04/13993003.02363-2019.Abstract N2-口服皮质类固醇（OCS）用于管理哮喘患者的哮喘病情和严重的，不受控制的Asthma，但Asthma，Asthma，Asthma，IS与不利影响有关。我们旨在描述西欧哮喘患者现实管理中的OCS使用模式。我们从2011年7月至2018年2月使用了来自法国，德国，意大利和英国数据库的电子病历。疼痛诊断≥12岁，诊断±6个月内≥1种非OCS哮喘药物，并且包括进入队列后≥6个月的可用数据≥6个月，并且包括进入队列后的≥90天。在随访期间，在90天的窗口中规定了高OCS≥450毫克的OCS≥450mg。总体上描述了在随访过程中的基线特征和OCS的使用。702685例哮喘患者，OCS使用者为14-44％，在随访期间的某个时候，OCS使用者为14-44％，有6-9％的OCS使用者为高OCS。在所有国家 /地区，高OC的年均使用率约为3％。高OCS用户的年度OCS处方平均为1-3个，平均每日OCS剂量为1.3-2.2 mg。 For patients who continued to meet the high use definition, daily OCS exposure was generally stable at 5.5–7.5 mg for at least 2 years, increasing the risk of adverse effects.Our study demonstrates that OCS use is relatively common across the four studied European countries. Data from this study may provide decisive clinical insights to inform primary care physicians and specialists involved in the management of severe, uncontrolled asthma.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Tran reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. King reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Sarkar reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Nan reports personal fees from AstraZeneca, personal fees from GlaxoSmithKline, outside the submitted work.Conflict of interest: Dr. Rubino reports personal fees from Evidera, outside the submitted work.Conflict of interest: Dr. O'Leary reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Muzwidzwa reports personal fees from IQVIA, outside the submitted work.Conflict of interest: Dr. Belton reports personal fees from AstraZeneca, outside the submitted work.Conflict of interest: Dr. Quint reports other from Imperial College London, outside the submitted work. ER -